Actively Recruiting
Regulatory Post-Marketing Surveillance Study for Brolucizumab
Led by Novartis Pharmaceuticals · Updated on 2025-01-14
3000
Participants Needed
28
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is an open-label, multicenter, single-arm, observational post-marketing surveillance.
CONDITIONS
Official Title
Regulatory Post-Marketing Surveillance Study for Brolucizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years with neovascular age-related macular degeneration prescribed brolucizumab according to approved local product information
- Patients who provide written informed consent after understanding the study purpose and nature
You will not qualify if you...
- Hypersensitivity to brolucizumab or any excipients
- Active or suspected ocular or periocular infection
- Active intraocular inflammation
- Participation in other investigational drug trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 28 locations
1
Novartis Investigative Site
Daegu, Dalseo Gu, South Korea, 42602
Actively Recruiting
2
Novartis Investigative Site
Goyang-si, Gyeonggi-do, South Korea, 10380
Actively Recruiting
3
Novartis Investigative Site
Guri-si, Gyeonggi-do, South Korea, 471-701
Actively Recruiting
4
Novartis Investigative Site
Suwon, Gyeonggi-do, South Korea, 16499
Actively Recruiting
5
Novartis Investigative Site
Iksan Si, Jeonlabuk Do, South Korea, 570-711
Actively Recruiting
6
Novartis Investigative Site
Daejeon, Korea, South Korea, 35015
Actively Recruiting
7
Novartis Investigative Site
Busan, South Korea, 47524
Actively Recruiting
8
Novartis Investigative Site
Busan, South Korea, 48064
Actively Recruiting
9
Novartis Investigative Site
Busan, South Korea, 49241
Actively Recruiting
10
Novartis Investigative Site
Daegu, South Korea, 705 718
Actively Recruiting
11
Novartis Investigative Site
Daegu, South Korea, 705703
Actively Recruiting
12
Novartis Investigative Site
Gwangju, South Korea, 61489
Actively Recruiting
13
Novartis Investigative Site
Gwangju, South Korea, 61932
Actively Recruiting
14
Novartis Investigative Site
Incheon, South Korea, 22332
Actively Recruiting
15
Novartis Investigative Site
Jeju City, South Korea, 63206
Actively Recruiting
16
Novartis Investigative Site
Pusan, South Korea, 614 735
Actively Recruiting
17
Novartis Investigative Site
Seoul, South Korea, 01000
Actively Recruiting
18
Novartis Investigative Site
Seoul, South Korea, 02841
Actively Recruiting
19
Novartis Investigative Site
Seoul, South Korea, 03080
Actively Recruiting
20
Novartis Investigative Site
Seoul, South Korea, 03722
Actively Recruiting
21
Novartis Investigative Site
Seoul, South Korea, 04401
Actively Recruiting
22
Novartis Investigative Site
Seoul, South Korea, 04763
Actively Recruiting
23
Novartis Investigative Site
Seoul, South Korea, 05368
Actively Recruiting
24
Novartis Investigative Site
Seoul, South Korea, 06273
Actively Recruiting
25
Novartis Investigative Site
Seoul, South Korea, 06351
Actively Recruiting
26
Novartis Investigative Site
Seoul, South Korea, 07301
Actively Recruiting
27
Novartis Investigative Site
Seoul, South Korea, 07441
Actively Recruiting
28
Novartis Investigative Site
Taegu, South Korea, 41944
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here